Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events

doi:10.13105/wjma.v3.i2.97

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12785)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-5) series.

Item

Count

PDF

584

WORD

325

HTML

5556

Figures (1-8)

151

Tables (1-5)

216

Sum=6832

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

524

Download

1480

Sum=2004

Publishing Process of This Article

Item

Count

Browse

1350

Download

2599

Sum=3949

Apr 26, 2015 (publication date) through Jul 3, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Meta-Analysis

ISSN

2308-3840

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Meta-Anal. Apr 26, 2015; 3(2): 97-117
Published online Apr 26, 2015. doi: 10.13105/wjma.v3.i2.97

Table 5 Prevention of adverse events associated with Helicobacter pylori eradication therapy in 28 treatment arms with adjunct probiotics n (%)

Probiotic strain	Any adverse events in probiotic	Any adverse events in controls	Antibiotic associated diarrhea in probiotic	Antibiotic associated diarrhea in controls	Ref.
S. boulardii I-745	3 (14)^b	12 (60)	1 (5)^a	6 (30)	Cremonini et al[53]
S. boulardii I-745	3 (1.5)	3 (1.7)	14 (6.9)^b	28 (15.6)	Duman et al[54]
S. boulardii I-745	14 (23)^b	37 (60)	9 (14.5)^a	19 (30.6)	Cindoruk et al[55]
S. boulardii I-745	4 (8)^a	13 (31)	nr	nr	Hurduc et al[56]
S. boulardii I-745	48 (14)	63 (19)	9 (3.3)^a	20 (6)	Song et al[57]
S. boulardii I-745 + MPA	30 (9)^b	63 (19)	11 (3)	20 (6)	Song et al[57]
S. boulardii I-745	nr	nr	nr	nr	Ozdil et al[58]
S. boulardii I-745	8 (16)^b	34 (68)	3 (6)	8 (16)	Chu et al[59]
S. boulardii I-745	nr	nr	10 (12.5)^a	21 (26)	Zojaji et al[60]
S. boulardii I-745	nr	nr	1 (2.8)^a	7 (20.6)	Kyriakos et al[61]
S. boulardii I-745	nr	nr	27 (22.5)^b	47 (39.1)	Zhao et al[62]
Clost. butyricum 588	6 (12.8)^a	15 (30)	nr	nr	Guo et al[63]
Clost. butyricum 588	nr	nr	1 ( 6)	2 (11.8)	Shimbo et al[64]
Clost. butyricum 588 (low dose)	nr	nr	1 (14)	3 (43)	Imase et al[65]
Clost. butyricum 588 (high dose)	nr	nr	0 (0)	3 (43)	Imase et al[65]
L. rhamnosus GG	26 (43)^a	37 (62)	8 (13.2)^b	29 (48.2)	Armuzzi et al[66]
L. rhamnosus GG	12 (40)^a	20 (66.6)	1 (3.3)^b	8 (26.6)	Armuzzi et al[67]
L. rhamnosus GG	3 (15)^b	12 (60)	1 (5)	6 (30)	Cremonini et al[53]
L. rhamnosus GG	18 (51)	13 (41)	2 ( 6)	6 (20)	Szajewska et al[68]
L. rhamnosus GG	10 (34)	10 (33)	4 (13.8)	6 (20)	Padilla Ruiz et al[69]
L. acidophilus Lb	6 (10)	6 (10)	nr	nr	Canducci et al[70]
L. acidophilus Lb	nr	nr	nr	nr	De Francesco et al[71]
L. acidophilus nr	4 (15)	5 (19)	nr	nr	Yeom et al[72]
L. reuteri 55730	0 (0)	0 (0)	nr	nr	Lionetti et al[73]
L. reuteri 55730	1 (5.9)^c	4 (26.7)	0 (0)^a	2 (13)	Scaccianoce et al[74]
L. reuteri 55730	nr	nr	10 (22)^b	26 (58)	Ojetti et al[75]
L. casei DG	5 (14.3)^a	13 (37)	0 (0)	3 (8.6)	Tursi et al[76]
L. casei DG	nr	nr	nr	nr	Giovannone et al[77]

^aP < 0.05,

^bP < 0.01,

^cTrend, 0.05 ≤P < 1.0. This strain is now designated: Saccharomyces boulardii CNCM I-745. nr: Not reported in paper/abstract. Numbers in table given as frequency and percent (%). S. boulardii: Saccharomcyes boulardii; L. rhamnosus: Lactobacillus rhamnosus.

Citation: McFarland LV, Malfertheiner P, Huang Y, Wang L. Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World J Meta-Anal 2015; 3(2): 97-117
URL: https://www.wjgnet.com/2308-3840/full/v3/i2/97.htm
DOI: https://dx.doi.org/10.13105/wjma.v3.i2.97